Literature DB >> 24142133

Study on the interactions between transplanted bone marrow-derived mesenchymal stem cells and regulatory T cells for the treatment of experimental colitis.

Dongmei Zuo1, Xingxing Liu, Zhexing Shou, Heng Fan, Qing Tang, Xueyun Duan, Dan Cao, Zhou Zou, Lijuan Zhang.   

Abstract

Accumulating evidence has established the use of mesenchymal stem cells (MSCs) as candidate cells for immunosuppressive therapy. Experimental studies have suggested that MSCs exert their immunomodulatory effects through the induction of regulatory T cells (Tregs) in vitro and in vivo. However, the interactions between MSCs and Tregs in inflammatory bowel disease (IBD) and whether MSCs can be used for the treatment of IBD remains to be elucidated. In this study, we aimed to investigate whether MSCs can be used for the treatment of IBD through the induction of Tregs. MSCs were isolated and identified by flow cytometry. The MSCs were transduced with a replication-defective recombinant lentiviral vector carrying GFP in order to be able to trace the injected cells in vivo. Prepared MSCs (1x106) were injected into rats with 2,4,6-trinitrobenzene sulfonic acid (TNBS)‑induced colitis via the tail vein; the control rats received phosphate-buffered saline (PBS) alone. Two weeks after the intravenous infusion, the frequency of CD4+CD25+Foxp3 cells in the peripheral blood was examined by flow cytometry. The colon was sectioned and analyzed for histopathological changes. Foxp3 mRNA expression was determined by real-time reverse-transcription polymerase chain reaction (qRT-PCR). In our study, the systemic infusion of MSCs significantly ameliorated the clinical and histopathologic severity of TNBS-induced colitis in contrast to the controls. There was an inverse regulation of mucosal and peripheral Foxp3 expression, suggesting that the MSCs redistributed the Tregs from the mucosa to the blood. Thus, MSCs exhibit immunomodulatory functions and may be used to ameliorate or treat IBD by redistributing regulatory T cells. Therefore, the interactions between transplanted bone marrow-derived MSCs and Tregs should be further investigated; MSCs have tremendous potential for use in the treatment of IBD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142133     DOI: 10.3892/ijmm.2013.1529

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  Differential Analysis of Serum Principal Components Treated with Compound Sophora Decoction and Related Compounds Based on High-Resolution Mass Spectrometry (HRMS).

Authors:  Wanjin Sun; Junjie Zhang; Conghui Zhou; Bin Yan; Quan Cai; Hongxia He; Xueyun Duan; Heng Fan
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-30       Impact factor: 2.629

2.  Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets.

Authors:  Stefano Pianta; Patrizia Bonassi Signoroni; Ivan Muradore; Melissa Francis Rodrigues; Daniele Rossi; Antonietta Silini; Ornella Parolini
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

Review 3.  Research Progress on Regulatory T Cells in Acute Kidney Injury.

Authors:  Yamei Wang; Yuhong Tao
Journal:  J Immunol Res       Date:  2015-07-26       Impact factor: 4.818

4.  Crosstalk between mesenchymal stem cells and macrophages in inflammatory bowel disease and associated colorectal cancer.

Authors:  Fei Mao; Jing-Jing Kang; Xiu Cai; Ning-Feng Ding; Yun-Bing Wu; Yong-Min Yan; Hui Qian; Xu Zhang; Wen-Rong Xu
Journal:  Contemp Oncol (Pozn)       Date:  2017-06-30

5.  Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats.

Authors:  Chun-Lan Xu; Yu Guo; Lei Qiao; Li Ma; Yi-Yi Cheng
Journal:  World J Gastroenterol       Date:  2018-02-14       Impact factor: 5.742

6.  Adipose-derived mesenchymal stem cells alleviate TNBS-induced colitis in rats by influencing intestinal epithelial cell regeneration, Wnt signaling, and T cell immunity.

Authors:  Jian-Guo Gao; Mo-Sang Yu; Meng-Meng Zhang; Xue-Wei Gu; Yue Ren; Xin-Xin Zhou; Dong Chen; Tian-Lian Yan; You-Ming Li; Xi Jin
Journal:  World J Gastroenterol       Date:  2020-07-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.